• Better use of Antibiotics • Breaking the optical transmission barriers
• Materials for clean air • Collaborative Spectrum Sharing • Food scanner
22-24 September 2014, Marseille, France
Focused on technologies and best practices, the conference will show where the real value of M2M is. - High level insights to rethink ecosystems, Big Data, platforms, connectivity, M2M security... - Lessons sharing of the most inspiring M2M implementations for Smart Grids, Smart Cities, Retail, Smart Home & Smart Devices.
22-24 September 2014, Lodz, Poland
The conference aims to enable researchers to build connections between different digital applications. The event will be held over three days, with presentations delivered by researchers from the international community, including presentations from keynote speakers and state-of-the-art lectures.
24 September 2014, Lyon, France
The BIO-TIC project has organised this workshop with the aim to identify technological, non-technological and market hurdles for the uptake of industrial biotechnology in CO2 based chemicals production and develop recommendations and solutions to overcome the identified hurdles. Input from market, policy and technological experts is crucial to help us develop recommendations which best answer the needs of industry and further build on the roadmaps.
CO2 is increasingly being considered by many as a commodity rather than a waste product. The largest current use for CO2 is currently in enhanced oil recovery. However, CO2 holds great potential as a feedstock for chemicals production using IB processes, especially in the EU where the research base is strong and where there is an abundance of CO2 available. CO2 is not part of the food chain so avoids any issues over food v fuel. However, public perception, and logistical and cost challenges in terms of CO2 transport and distribution could hamper the potential of CO2 to be used for chemicals and substantial R&D is needed to bring many opportunities to fruition.
23 September 2014, London, UK
The volume of data is exploding, and that is challenging drug makers' ability to transform big data into additional revenue. But companies who can exploit big data and analytics will have the potential to improve their productivity and efficiency, especially in the discovery, research and development of new products, experts say. McKinsey has predicted big data could reduce research and development costs for pharmaceutical makers by $40 billion to $70 billion. They anticipate that data will form the cornerstone of future value-based assessment and also be used for gaining market access, and enhance competitiveness.